# ETER100 (benmelstobart): what clinicians are saying

> 44 statements from 6 sources (1 video, 3 posts, 2 papers), each linked to its source. Commentary checked Nov 22, 2026.

## Report

- Trial: A Randomized, Positive Parallel Controlled, Multicenter Phase III Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer
- NCT ID: NCT04523272
- Registry: https://clinicaltrials.gov/study/NCT04523272
- Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Phase: Phase 3
- Status: Unknown
- Drugs tested: benmelstobart plus anlotinib
- Indication: first-line advanced renal cell carcinoma
- Version: v1.0.0, edition 1
- Accepted: 2026-11-22 UTC
- Last checked: 2026-11-22 UTC
- Release hash: ea0a93bd4ad84bb661b9e72ce64ba4f876d1bfb42716fb3a87b03adb530e3743

## Counts

- Commentary sources screened: 24
- Sources cited by verified statements: 6
- Verified statements: 44
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 0
- Findings: 4
- Named people in screened sources (unnamed speakers and accounts not counted): 3
- Speakers cited: 2
- Cited speakers with a verified identity: 2
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 0
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 0
- Organisational or shared accounts (not counted as people): 1

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

A speaker in the discussion reads ETER100 favorably because its results resemble existing combinations, yet would forgo PD-L1 inhibition if PD-1 agents were available. They speculate that the low complete-response rate could reflect a class-activity difference, without comparative proof. An unverified account separately suggests a change in treatment positioning—a different emphasis, not a documented direct debate. The speaker describes overall survival as immature at the time, not as showing an absence of survival benefit.

## Findings (titles)

- F1. ETER100: a speaker likens it to options but avoids PD-L1 with PD-1 access
  - 8 statements in 1 source, a podcast or video.
  - No named speaker is counted in this finding: its title's view comes from speakers the source does not name.
  - No named clinician · accounts and unnamed speakers.
- F2. ETER100: what a speaker highlights in the PFS benefit versus Sunitinib
  - 11 statements from 1 speaker in 4 sources, 1 of them a podcast or video.
  - The one named speaker in this finding holds this view.
  - No named clinician · accounts and unnamed speakers.
- F3. ETER100 tolerability: what a speaker relays from the presentation
  - 15 statements from 1 speaker in 3 sources.
  - The one named speaker in this finding holds this view.
  - No named clinician · accounts and unnamed speakers.

### Beyond the trial population

- F4. Advanced RCC: how a speaker tailors care with extreme cross-trial caution
  - 5 statements from 1 speaker in 1 source.
  - The one named speaker in this finding holds this view.
  - No named clinician · accounts and unnamed speakers.

1 of the 4 findings and 5 of the 44 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 8 | 1 | 1 | 0 | 4 |
| F2 | 11 | 7 | 4 | 1 | 4 |
| F3 | 15 | 13 | 3 | 1 | 4 |
| F4 | 5 | 4 | 1 | 1 | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 3 | 1 | 0 | 4 | 0 | 8 | 1 | 1 podcast or video |
| F2 | 5 | 0 | 0 | 3 | 3 | 14 | 1 | 2 posts and articles, 1 podcast or video, 1 publication |
| F3 | 8 | 4 | 0 | 0 | 3 | 16 | 5 | 1 post or article, 2 publications |
| F4 | 4 | 0 | 0 | 1 | 0 | 5 | 0 | 1 post or article |

### Trial dimensions

- Primary endpoint: Progression free survival (PFS) evaluated by Independent Review Committee(IRC): F1 (1 shared claims), F2 (4 shared claims)
- Secondary endpoints: F2 (1 shared claims)
- Population and setting: F1 (1 shared claims), F2 (1 shared claims)
- The comparison: F1 (5 shared claims), F2 (6 shared claims)
- Safety and tolerability: F3 (1 shared claims)
- Design and conduct: F1 (2 shared claims), F2 (2 shared claims)

## Abbreviations

- HCP: healthcare professional
- IRC: independent review committee
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians
- PD-L1: programmed death-ligand 1
- PFS: progression-free survival
- RCC: renal cell carcinoma

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 4 | Titles free |
| Detailed analysis | 6 sections | Paid |
| Verified statements with short source quotes and links | 44 | Paid |
| Who said each statement: the cited speakers | 2 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 0 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 2 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 8 | Free |
| Sources with links | 6 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 0 of the 2 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

8 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Progression free survival (PFS) evaluated by Independent Review Committee(IRC) | discussed | 4 | 3 |
| Secondary endpoints | discussed | 1 | 1 |
| Population and setting | discussed | 1 | 1 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 7 | 3 |
| Safety and tolerability | discussed | 1 | 1 |
| Design and conduct | discussed | 2 | 1 |
| Overall response, complete response and checkpoint-class activity | discussed | 4 | 2 |
| Cross-trial interpretation and patient-centered selection in advanced kidney cancer | discussed | 5 | 1 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 9 statements · 21%** | | | |
| YouTube | 9 | 1 | 1 |
| **Posts · 8 statements · 18%** | | | |
| X threads | 8 | 3 | 23 |
| **Primary sources · 27 statements · 61%** (cited for context, not screened) | | | |
| Publications (primary source, cited for context) | 27 | 2 | not screened |

- Screened window: 2021-11-18 to 2026-11-21
- Cited window: 2021-11-19 to 2025-09-16
- Retrieved: 2026-11-22

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Randomized, Positive Parallel Controlled, Multicenter Phase III Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer
- Registry: NCT04523272 (https://clinicaltrials.gov/study/NCT04523272)
- Study IDs: TQB2450-III-07
- Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Unknown
- Enrollment: 528 (actual)
- Start: 2020-08-25 (actual)
- Primary completion: 2025-06 (estimated)
- Primary endpoint: Progression free survival (PFS) evaluated by Independent Review Committee(IRC) (up to 60 weeks)
- Intervention: TQB2450 (drug)
- Intervention: Anlotinib (drug)
- Intervention: Sunitinib (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- 16 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 25 sources about other trials or topics are not included.
- The substantive commentary summarized here comes from three X threads and one video discussion. These sources cannot establish how common a view is among HCPs, and reposts are not additional independent endorsements.
- Discussion using unnamed trial references, alternative spellings or other terminology may have been missed. Silence on a topic is not evidence that clinicians have no view.
- The video speaker cannot be named, and the video's date is not provided. The November 2021, September 2024 and September 2025 posts must not be interpreted as a sequence showing changing opinion.
- Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.
- The video and the 2021 selection thread do not name ETER100. The former addresses its regimen and comparator; the latter supplies broader advanced-kidney-cancer treatment-selection context rather than trial-specific results commentary.
- The complete-response concern has no numerical rate in the discussion, and the comparisons with other combinations are not head-to-head evidence. The speaker's checkpoint-class explanation remains speculative.
- The linked renal publication supplies practical context, not an independently attributed HCP practice survey. Its post-hoc, single-trial analysis may miss subclinical injury, does not resolve long-term renal outcomes, and does not validate routine use of its proposed monitoring schedule.
- The primary study population was Chinese and concerned first-line advanced clear-cell RCC; extrapolation beyond that setting requires caution.
- No full protocol or exact product labels accompany these sources. Jurisdiction-specific approval, access and prescribing conclusions cannot be drawn.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-22 UTC: current edition

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-22 UTC. No changes.

## Offer

- Size: Focused · 44 verified statements · none from confirmed clinicians
- Not for sale: This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested. No order can be placed for it, by any route; a later edition that reaches the minimum is for sale at its normal price. Follow the change feed: https://www.erudio.com/reports/eter100-nct04523272/feed.json
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=eter100-nct04523272

## Cite

Erudio Health. ETER100 (NCT04523272): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 22, 2026. https://www.erudio.com/reports/eter100-nct04523272

## Questions

### How much does the ETER100 report cost?

This edition is below our minimum for clinicians and sources, so it is not for sale yet. Contact us if you are still interested.

### What does the ETER100 report cover?

44 statements from 6 sources (1 video, 3 posts, 2 papers), each linked to its source. Commentary checked Nov 22, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the ETER100 report?

Its preview, yes: get_report_card({ "slug": "eter100-nct04523272" }) on https://mcp.erudio.com/free, with no sign-in. It cannot be ordered yet. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the ETER100 report?

Edition 1 (version 1.0.0), accepted Nov 22, 2026 UTC; last checked for new commentary Nov 22, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/eter100-nct04523272.json
- Markdown: https://www.erudio.com/reports/eter100-nct04523272.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/eter100-nct04523272/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "eter100-nct04523272"}`
